报价延迟最少15分钟:2026/04/21 23:57 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.8235 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.80/-0.59
|
|
企业价值
94.22M
|
| 资产负债 |
|
每股账面净值
0.69
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
190.00K
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD). |
